The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis

Giaquinto, 2022, Breast cancer statistics, 2022, Ca - Cancer J Clin, 72, 524, 10.3322/caac.21754

2020

Albanell, 2022, Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: geicam/2014–12 (FLIPPER), Eur J Cancer, 161, 26, 10.1016/j.ejca.2021.11.010

Goetz, 2022, LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC), Ann Oncol, 33, S1384, 10.1016/j.annonc.2022.08.009

Goetz, 2021, Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials, Breast Cancer Res Treat, 186, 417, 10.1007/s10549-020-06029-y

Hortobagyi, 2022, Overall survival with ribociclib plus letrozole in advanced breast cancer, N Engl J Med, 386, 942, 10.1056/NEJMoa2114663

Slamon, 2018, Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3, J Clin Oncol, 36, 2465, 10.1200/JCO.2018.78.9909

Sledge, 2020, The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial, JAMA Oncol, 6, 116, 10.1001/jamaoncol.2019.4782

Turner, 2018, Overall survival with palbociclib and fulvestrant in advanced breast cancer, N Engl J Med, 379, 1926, 10.1056/NEJMoa1810527

Zhang, 2020, MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study, Ther Adv Med Oncol, 12, 10.1177/1758835920963925

Finn, 2022, J Clin Oncol, 40, LBA1003, 10.1200/JCO.2022.40.17_suppl.LBA1003

Burstein, 2021, Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update, J Clin Oncol, 39, 3959, 10.1200/JCO.21.01392

Clifton, 2019, Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population, Breast Cancer Res Treat, 175, 667, 10.1007/s10549-019-05181-4

Wilkie, 2020, Progression-free survival for real-world use of palbociclib in hormone receptor-positive metastatic breast cancer, Clin Breast Cancer, 20, 33, 10.1016/j.clbc.2019.06.010

Olazagasti, 2023, A deep dive into CDK4/6 inhibitors: evaluating real world toxicities and treatment paradigms in the elderly population, J Oncol Pharm Pract, 29, 14, 10.1177/10781552211050106

Low, 2022, Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia, Ther Adv Med Oncol, 14, 10.1177/17588359221139678

Howie, 2019, Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis, J Clin Oncol, 37, 3475, 10.1200/JCO.18.02217

Mohile, 2018, Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric Oncology, J Clin Oncol, 36, 2326, 10.1200/JCO.2018.78.8687

Kaufman, 2018, Health-related quality of life (HRQoL) in MONARCH 2: abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy, J Clin Oncol, 36, 1049, 10.1200/JCO.2018.36.15_suppl.1049

Battisti, 2018, Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: young International Society of Geriatric Oncology review paper, Ther Adv Med Oncol, 10, 10.1177/1758835918809610

Mastrantoni, 2023, The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis, EClinicalMedicine, 56, 10.1016/j.eclinm.2023.101824

De Laurentiis, 2021, Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population [published correction appears in Breast Cancer Res Treat. 2021 Oct 8;:], Breast Cancer Res Treat, 189, 689, 10.1007/s10549-021-06334-0

Price, 2022, Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting, Curr Med Res Opin, 38, 1319, 10.1080/03007995.2022.2073122

Goyal, 2023, Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study, Cancer, 129, 1051, 10.1002/cncr.34675